Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo
Go back to Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 127.74 -0.38 (0.3%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.12 | 52 Week High | $118.49 | |||
| Open | $128.13 | 52 Week Low | $55.00 | |||
| Day High | $128.20 | P/E | N/A | |||
| Day Low | $126.06 | EPS | $-0.56 | |||
| Volume | 700,682 | |||||
